Abstract:Abstract Immune checkpoint blockade (ICB) has revolutionized cancer therapy demonstrating durable responses in multiple tumor types, however only a subset of patients respond, in part due to mechanisms that drive T cell dysfunction. HPK1 is a key inhibitory signaling node associated with T cell exhaustion that is activated in response to T cell receptor engagement (signal 1). HPK1 is thus distinct from inhibitory checkpoint receptors which require surface receptor expression, antigen recognition (signal 1) and costimulatory engagement (signal 2) for activity. HPK1 therefore has potential for broader activity across T cell subsets independent of checkpoint engagement. Selectivity is a critical parameter for the optimal profile of an HPK1 inhibitor because many kinases are positive regulators of T cell signaling and can be antagonistic if inhibited. Utilizing a structure-based drug design approach, we identified compound 1 a highly potent (pSLP76 IC50=55nM) inhibitor of HPK1, which displayed no functional antagonistic effects in human T cells up to 30μM. We attributed this its highly selective nature, possessing >80-fold selectivity against other MAP4K family members, and >25-fold selectivity against all other kinases tested. We demonstrated an inverse correlation between inhibition of pSLP76 and increase in IL-2, IFNg and proliferation in human T cells. We report a novel role for HPK1 in regulating T cell exhaustion in a human ex vivo assay. Compound 1 treatment prevents T cell exhaustion at > 0.1uM and can restore aspects of already exhausted T cells, most notably rescue of cytotoxicity. RNAseq and nuclear localization assays reveal for the first time that HPK1i mechanistically restores AP-1 signaling which enables heterodimerization with NFAT restoring human T cell functionality. We present data demonstrating that our HPK1 inhibitor elevates anti-tumor immunity in multiple syngeneic mouse models including MCA205, CT26 and EMT6. In vitro IC50 correlates with in vivo decrease of pSLP76 in tumors and blood of syngeneic models associated with efficacy. Immunophenotyping from syngeneic tumors treated with compound 1 shows a two-fold increase in CD8+ T cells and most significantly enhanced cytokine production in T cells. In patient NSCLC samples Compound 1 has single agent and combination activity with Durvalumab restoring cytokine production. These results thus reveal the role of AP-1/NFAT signaling in HPK1 biology and highlight the importance of HPK1 in T cell exhaustion in both healthy donor and NSCLC patient tumor T cells, potentially limiting responses to ICB. Citation Format: Deanna A. Mele, Neil Grimster, Gayathri Bommakanti, Jason Shields, Lucas Morrill, Kathryn Giblin, Maryann SanMartin, Yanjun Wang, Minwei Ye, Iswarya KarapaReddy, Kun Song, Theresa Proia, Niresh Hariparsad, Ryan Richards, Nadia Luheshi, Simon T. Barry, Stephen Fawell. First disclosure of a highly potent and selective HPK1 inhibitor that rescues T cell exhaustion [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 3453.

Hematopoietic Progenitor Kinase1 (HPK1) Mediates T Cell Dysfunction and Is a Druggable Target for T Cell-Based Immunotherapies

Opportunities and challenges for targeting HPK1 in cancer immunotherapy

Hematopoietic Progenitor Kinase 1 in Tumor Immunology: A Medicinal Chemistry Perspective.

Pharmacological inhibition of hematopoietic progenitor kinase 1 positively regulates T-cell function

Current strategies for targeting HPK1 in cancer and the barriers to preclinical progress

The HPK1 Inhibitor A-745 Verifies the Potential of Modulating T Cell Kinase Signaling for Immunotherapy

The Development of Small-Molecule Inhibitors Targeting HPK1

Novel hematopoietic progenitor kinase 1 inhibitor KHK-6 enhances T-cell activation

Discovery of Novel PROTAC-Based HPK1 Degraders with High Potency and Selectivity for Cancer Immunotherapy

An Updated Review of Small-Molecule HPK1 Kinase Inhibitors (2016-Present)

Abstract 2654: HPK1 inhibits CD8+ T cell effector gene expression following T cell activation

Discovery of Potent and selective HPK1 Inhibitors Based on the 2,4-disubstituted Pyrimidine Scaffold with Immune Modulatory properties for Ameliorating T cell exhaustion

HPK1 Influences Regulatory T Cell Functions

Abstract 3453: First disclosure of a highly potent and selective HPK1 inhibitor that rescues T cell exhaustion

Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor

Design and synthesis of 1H-pyrazolo[3,4-d]pyrimidine derivatives as hematopoietic progenitor kinase 1 (HPK1) inhibitors

Development of High-Throughput Assays for Evaluation of Hematopoietic Progenitor Kinase 1 Inhibitors

Design and synthesis of 1H-pyrazolo[3,4-<i>d</i>]pyrimidine derivatives as hematopoietic progenitor kinase 1 (HPK1) inhibitors

Abstract 3517: Pharmacologic inhibition of HPK1 kinase activity enhances immune cell activation and T cell mediated anti-tumor activity

Discovery of Hematopoietic Progenitor Kinase 1 Inhibitors Using Machine Learning-Based Screening and Free Energy Perturbation.

An HPK1 Inhibitor Enhanced the Tumour Response to Anti-Pd-1 Immunotherapy in Non-Hodgkin’s Lymphoma